RNA interference gene therapy for the treatment of cardiovascular disease

Abstract

The constant progress in molecular biology and genetic engineering technologies within the field of cardiovascular pharmacology, along with the introduction of clinically applied drugs based on these advancements, compels us to reconsider our current understanding in this area. This article aims to provide an update on the underlying mechanisms, pharmacological design, and the clinical applications tested so far, and also to address the safety concerns associated with drugs that utilize RNA interference technology.